Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations

Accompanying the increased use of biological and non-biological antirheumatic drugs, a greater number of cases of hepatitis B virus (HBV) reactivation have been reported in inactive hepatitis B surface antigen (HBsAg) carriers and also in HBsAg-negative patients who have resolved HBV infection. The...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	World journal of gastroenterology : WJG Ročník 21; číslo 36; s. 10274
Hlavní autoři:	Mori, Shunsuke, Fujiyama, Shigetoshi
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 28.09.2015
Témata:	Antirheumatic Agents - adverse effects Antiviral Agents - therapeutic use Hepatitis B - diagnosis Hepatitis B - epidemiology Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B - virology Hepatitis B virus - drug effects Hepatitis B virus - immunology Hepatitis B virus - pathogenicity Humans Immunocompromised Host Prevalence Recurrence Rheumatic Diseases - diagnosis Rheumatic Diseases - drug therapy Rheumatic Diseases - epidemiology Rheumatic Diseases - immunology Risk Assessment Risk Factors Virus Activation - drug effects Reactivation Resolved hepatitis B virus infection Hepatitis B virus Occult hepatitis B virus carrier Antirheumatic therapy
ISSN:	2219-2840, 2219-2840
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!